Literature DB >> 24721827

Effects of topical application of a recombinant staphylococcal enterotoxin A on DNCB and dust mite extract-induced atopic dermatitis-like lesions in a murine model.

Byung Soo Kim1, Jin Kyeong Choi2, Han Jin Jung3, Kyung Hea Park3, Yong Hyun Jang3, Weon Ju Lee3, Seok-Jong Lee3, Sang-Hyun Kim2, Hee Young Kang4, Jung Min Kim4, Hyun Jung Lim5, Do Won Kim3.   

Abstract

BACKGROUND: Atopic dermatitis (AD) is a chronic inflammatory skin disease with biphasic T cell-mediated abnormalities. Staphylococcal superantigens contribute to the exacerbation of inflammation in AD. The underlying immunopathological mechanisms are not fully understood.
OBJECTIVE: To determine whether epicutaneous application of recombinant staphylococcal enterotoxin A (rSEA) would exacerbate AD-like allergic inflammation induced by 2, 4-dinitrochlorobenzene (DNCB) and house dust mite extract (Dermatophagoides farinae extract, DFE) in a murine model.
MATERIALS AND METHODS: We first established an AD-like model using BALB/c mice exposed to DNCB/DFE on the ear. Next, Staphylococcus (S.) aureus or rSEA were topically applied to the mice. We evaluated the clinical and histopathological features of the animals. Serum immunoglobulin levels were also measured. In addition, real-time PCR analysis of cytokines produced by T cell subsets in the ears was conducted.
RESULTS: Mice treated with S. aureus and rSEA had more severe clinical symptoms, including increased mean dermatitis scores and ear thickness, compared to animals with only AD-like lesions. Total IgE, IgG2a and serum histamine levels were increased in all groups except the normal control group. The S. aureus- and rSEA-treated groups showed increased levels of cytokines such as IL-4, IL-13, INF-γ, IL-17, and IL-18. In particular, increased cytokine expression was more conspicuous in the rSEA-treated group than in mice exposed to S. aureus.
CONCLUSION: The results of this study showed that topical exposure to rSEA as well as SEA-producing S. aureus aggravate atopic skin inflammation. This may be associated with the induction of a mixed Th1/Th2 type dermatitis.

Entities:  

Keywords:  Atopic dermatitis; Murine model; Staphylococcal enterotoxin A; Staphylococcus aureus

Mesh:

Substances:

Year:  2014        PMID: 24721827     DOI: 10.1684/ejd.2014.2302

Source DB:  PubMed          Journal:  Eur J Dermatol        ISSN: 1167-1122            Impact factor:   3.328


  6 in total

Review 1.  IL-18 and Cutaneous Inflammatory Diseases.

Authors:  Ji Hyun Lee; Dae Ho Cho; Hyun Jeong Park
Journal:  Int J Mol Sci       Date:  2015-12-09       Impact factor: 5.923

2.  Effect of Dangguibohyul-Tang, a Mixed Extract of Astragalus membranaceus and Angelica sinensis, on Allergic and Inflammatory Skin Reaction Compared with Single Extracts of Astragalus membranaceus or Angelica sinensis.

Authors:  You Yeon Choi; Mi Hye Kim; Jongki Hong; Kyuseok Kim; Woong Mo Yang
Journal:  Evid Based Complement Alternat Med       Date:  2016-03-08       Impact factor: 2.629

Review 3.  Molecular Mechanisms of Cutaneous Inflammatory Disorder: Atopic Dermatitis.

Authors:  Jung Eun Kim; Jong Sic Kim; Dae Ho Cho; Hyun Jeong Park
Journal:  Int J Mol Sci       Date:  2016-07-30       Impact factor: 5.923

Review 4.  The Pathogenetic Effect of Natural and Bacterial Toxins on Atopic Dermatitis.

Authors:  Kyung-Duck Park; Sok Cheon Pak; Kwan-Kyu Park
Journal:  Toxins (Basel)       Date:  2016-12-23       Impact factor: 4.546

Review 5.  Exploring the Role of Staphylococcus Aureus Toxins in Atopic Dermatitis.

Authors:  Fabio Seiti Yamada Yoshikawa; Josenilson Feitosa de Lima; Maria Notomi Sato; Yasmin Álefe Leuzzi Ramos; Valeria Aoki; Raquel Leao Orfali
Journal:  Toxins (Basel)       Date:  2019-06-05       Impact factor: 4.546

6.  Construction, Expression, and Characterization of rSEA-EGF and In Vitro Evaluation of its Antitumor Activity Against Nasopharyngeal Cancer.

Authors:  Xueting Liu; Liping Zeng; Zhongqiu Zhao; Yang Xie; Shan Wang; Junyan Zhang; Ying He; Zehong Zou; Jianguo Zhang; Ailin Tao
Journal:  Technol Cancer Res Treat       Date:  2018-01-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.